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Abstract
Neural stem cells hold the key to innovative new treatments for age-associated degeneration and
traumatic injury to the brain and spinal cord. We hypothesized that the in vivo induced pluripotent
stem cells or neural stem cells through "forced gene expression" can be used to repair damaged
brain areas or treat degenerative diseases. Hopefully, these in vivo patient-specific stem cells can
bring a new avenue for cell replacement therapies.
Background
One characteristic of many neurodegenerative diseases –
which include stroke, brain trauma, spinal cord injury,
amyotrophic lateral sclerosis, Huntington's disease,
Alzheimer's disease, and Parkinson's disease – is neuro-
nal-cell death. At the moment, few or no effective options
are available for their treatments. Neural stem cells hold
the key to innovative new treatments for age-associated
degeneration and traumatic injury to the brain and spinal
cord. In this way, induced pluripotent stem cells (iPSCs)
have been successfully produced in both mouse [1-4] and
human somatic cells [5,6]. The artificially generated iPSCs
were remarkably similar to other naturally isolated stem
cells, and thus can give birth to all kinds of cell types,
including neurons. The potential of inducing a non-
pluripotent cell in order to become a pluripotent stem cell
therefore opens a new avenue beyond transplantation in
cell-replacement therapies to degenerative diseases. Here
we propose that one important application is to produce
neural stem cells from differentiated neurons in vivo in the
central nervous system, and to repair the dysfunctional
neural circuits, whether caused by aging, disease or a knife
cut.
Neural stem cells have been transplanted into the brain
for some time now for therapeutic purpose. The survival
and integration of embryonic stem cells or adult stem
cells, however, are largely challenged by the immune
rejection, and may run into ethical issues. Additionally,
the pharmacologically or physiologically enhanced
endogenous neurogenesis is limited to hippocampus and
subventricular zone, both of which are restricted to spe-
cific areas, and are less likely to be helpful in many brain
diseased conditions. Thus, if the genetically "forced" cell
type transformation can be repeated in vivo on nervous
system tissues, the newly generated neurons are free from
immune rejection, and may have better chances of inte-
gration into original circuits.
Hypothesis
The in vivo induced pluripotent stem cells or neural stem
cells through "forced gene expression" can be used to
repair damaged brain areas or treat degenerative diseases.
Several families of genes have been identified and used on
induction of iPSCs, such as Oct3/4, Sox, Klf, Myc, Nanog
and LIN28. We hypothesize that these genes can also be
used in producing in vivo iPSCs or induced neural stem
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cells. Further genes, however, are required to produce fate
determined neural cell lineages in a well-controlled man-
ner. One challenge will be balancing the effects of differ-
ent transcription factors to make these induced stem cells
be pluripotent enough to give birth to neurons or glial
cells at proper sites. However, slow work can lead to
tumor formation.
For cell therapy, it should be noted that teratoma forma-
tion is an inherent feature of iPSCs. However the use of
non-viral submission may eliminate such risks. As this
tumorigenic activity is lost following differentiation,
pharmacological approaches and genetic manipulation
can be adopted to promote the neural differentiation.
Finally, careful physiological evaluations are required to
confirm the same function of neurons as if induced from
a glia.
Testing the hypothesis
The first step will be the induction of neurons or glial cells
in culture into neural stem cells or pluripotent stem cells,
using similar transcription factors that have succeed in
skin cells, for example, or to indentify extra transcription
factors required. Then either viral transfection or electro-
poration could be adopted for in vivo gene transfer,
"inducing" neural cells inside the brain into stem cells.
Lastly the therapeutic values of these newly generated
neurons have to be tested, to see if they can bring any
functional outcomes.
Implications of the hypothesis
Gene therapy on the brain has been well developed. Viral
vectors including lentivirus and retrovirus were widely
used, both of which are used in producing the iPSCs [5,6].
Furthermore, the non-viral approaches such as electropo-
ration can achieve good localization as well as high effi-
ciency in both embryo and adult brain [7]. Liposome [8]
or nanoparticles [9] based gene submission also offer
strong supports for genetic manipulations in vivo. Other
potential methods that could be used are sonoporation
that adopt ultrasound in mediating the gene transfer [10-
12]. Theoretically, sonoporation can be applied on any
perfused tissue or organ, including deep brain areas;
what's more, this non-invasive approach is free of micro-
injection into the brain and the drugs can be embedded
into "blood-brain-barrier-free" bubbles, taken orally or
injected intravenously for brain submission. All these
methods that submit genes or molecules into specific
areas provide eligible avenues in producing iPSCs or neu-
ral stem cells locally inside the brain. Hopefully, these in
vivo patient-specific stem cells can bring a new avenue for
cell replacement therapies.
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